Prognostic Factors in Multiple Sclerosis

International Review of Neurobiology

Volumn 79, Issue , 2007, Pages 423-447

  Bergamaschi, Roberto ^a  

^a C MONDINO NATIONAL NEUROLOGICAL INSTITUTE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER;

DISABILITY; FEMALE; HUMAN; MALE; METABOLISM; MULTIPLE SCLEROSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; ONSET AGE; PATHOPHYSIOLOGY; PROGNOSIS; REVIEW; SEXUAL DEVELOPMENT;

AGE OF ONSET; BIOLOGICAL MARKERS; DISABILITY EVALUATION; FEMALE; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; MULTIPLE SCLEROSIS; PROGNOSIS; SEX CHARACTERISTICS;

EID: 34248654402     PISSN: 00747742     EISSN: None     Source Type: Book Series    
DOI: 10.1016/S0074-7742(07)79019-0     Document Type: Review

References (102)

1. Amato M.P., Ponziani G., Bartolozzi M.L., and Siracusa G. A prospective study on the natural history of multiple sclerosis: Clues to the conduct and interpretation of clinical trials. J. Neurol. Sci. 168 (1999) 96-106
2. Annunziata P., Giorgio A., De Santi L., Zipoli V., Portaccio E., Amato M.P., Clerici R., Scarpini E., Moscato G., Iudice A., Vacca G., Orefice G., et al. Absence of cerebrospinal fluid oligoclonal bands is associated with delayed disability progression in relapsing-remitting MS patients treated with interferon-beta. J. Neurol. Sci. 244 (2006) 97-102
3. Avasarala J.R., Cross A.H., and Trotter J.L. Oligoclonal band number as a marker for prognosis in multiple sclerosis. Arch. Neurol. 58 12 (2001) 2044-2045
4. Barkhof F., Filippi M., Miller D.H., Scheltens P., Campi A., Polman C.H., Comi G., Ader H.J., Losseff N., and Valk J. Comparison of MRI criteria at first presentation to predict conversion to clinically definite multiple sclerosis. Brain 120 (1997) 2059-2069
5. Beck R.W. The optic neuritis treatment trial: Three-year follow-up results. Arch. Ophthalmol. 113 2 (1995) 136-137
6. Beck R.W., Trobe J.D., Moke P.S., Gal R.L., Xing D., and Optic N.S.G. High and low risk profiles for the development of multiple sclerosis within 10 years after optic neuritis: Experience of the Optic Neuritis Treatment Trial. Arch. Ophthalmol. 121 (2003) 944-949
7. Bergamaschi R., Romani A., Tonietti S., Citterio A., Berzuini C., and Cosi V. Usefulness of Bayesian graphical models for early prediction of disease progression in multiple sclerosis. Neurol. Sci. 21 4 Suppl. 2 (2000) S819-S823
8. Bergamaschi R., Berzuini C., Romani A., and Cosi V. Predicting secondary progression in relapsing-remitting multiple sclerosis: A Bayesian analysis. J. Neurol. Sci. 189 (2001) 13-21
9. Bergamaschi R., Montomoli C., Candeloro E., Fratti C., Citterio A., and Cosi V. Disability and mortality in a cohort of multiple sclerosis patients: A reappraisal. Neuroepidemiology 25 (2005) 15-18
10. Berger T., Rubner P., Schautzer F., Egg R., Ulmer H., Mayringer I., Dilitz E., Deisenhammer F., and Reindl M. Antimyelin antibodies as a predictor of clinically definite multiple sclerosis after a first demyelinating event. N. Engl. J. Med. 349 (2003) 139-145
11. Berzuini C., and Larizza C. A unified approach for modelling longitudinal and failure time data, with application in medical monitoring. IEEE Trans Pattern Anal. Mach. Intell. 2 (1996) 109-123
12. Boeije H.R., and Janssens A.C. 'It might happen or it might not': How patients with multiple sclerosis explain their perception of prognostic risk. Soc. Sci. Med. 59 (2004) 861-868
13. Brex P.A., O'Riordan J.I., Miszkiel K.A., Moseley I.F., Thompson A.J., Plant G.T., and Miller D.H. Multisequence MRI in clinically isolated syndromes and the early development of MS. Neurology 53 6 (1999) 1184-1190
14. Brex P.A., Ciccarelli O., O'Riordan J.I., Sailer M., Thompson A.J., and Miller D.H. A longitudinal study of abnormalities on MRI and disability from multiple sclerosis. N. Engl. J. Med. 346 3 (2002) 158-164
15. Broman T., Andersen O., and Bergmann L. Clinical studies on multiple sclerosis. I. Presentation of an incidence material from Gothenburg. Acta Neurol. Scand. 63 (1981) 6-33
16. Cardona-Gomez G.P., Mendez P., DonCarlos L.L., Azcoitia I., and Garcia-Segura L.M. Interactions of estrogens and insulin-like growth factor-I in the brain: Implications for neuroprotection. Brain Res. Brain Res. Rev. 37 (2002) 320-334
17. CHAMPS Study Group. MRI predictors of early conversion to clinically definite multiple sclerosis in CHAMPS placebo group. Neurology 59 (2002) 998-1005
18. Citterio A., Azan G., Bergamaschi R., Erbetta A., and Cosi V. Multiple sclerosis: Disability and mortality in a cohort of clinically diagnosed patients. Neuroepidemiology 8 (1989) 249-253
19. Comi G., Filippi M., Barkhof F., Comi G., Filippi M., Barkhof F., Durelli L., Edan G., Fernandez O., Hartung H.-P., Seeldrayers P., Sørensen P.S., et al. Effect of early interferon treatment on conversion to definite multiple sclerosis: A randomised study. Lancet 357 9268 (2001) 1576-1582
20. Confavreux C., Aimard G., and Devic M. Course and prognosis of multiple sclerosis assessed by the computerised data processing of 349 patients. Brain 103 (1980) 281-300
21. Confavreux C., Hutchinson M., Hours M.M., Cortinovis-Tourniaire P., and Moreau T. Rate of pregnancy-related relapse in multiple sclerosis. Pregnancy in Multiple Sclerosis Group. N. Engl. J. Med. 339 (1998) 285-291
22. Confavreux C., Vukusic S., Moreau T., and Adeleine P. Relapses and progression of disability in multiple sclerosis. N. Engl. J. Med. 343 20 (2000) 1430-1438
23. Confavreux C., Vukusic S., and Adeleine P. Early clinical predictors and progression of irreversible disability in multiple sclerosis: An amnesic process. Brain 126 (2003) 770-782
24. Dalton C.M., Brex P.A., Jenkins R., Fox N.C., Miszkiel K.A., Crum W.R., O'Riordan J.I., Plant G.T., Thompson A.J., and Miller D.H. Progressive Ventricular enlargement in patients with clinically isolated syndromes is associated with the early development of multiple sclerosis. J. Neurol. Neurosurg. Psychiatry 73 (2002) 141-147
25. De Stefano N., Battaglini M., Stromillo M.L., Zipoli V., Bartolozzi M.L., Guidi L., Siracusa G., Portaccio E., Giorgio A., Sorbi S., Federico A., and Amato M.P. Brain damage as detected by magnetization transfer imaging is less pronounced in benign than in early relapsing multiple sclerosis. Brain 129 (2006) 2008-2016
26. Deryck O., Ketelaer P., and Dubois B. Clinical characteristics and long term prognosis in early onset multiple sclerosis. Epub 2006 March 6. J. Neurol. 253 (2006) 720-723
27. Detels R., Clark V.A., Valdiviezo N.L., Visscher B.R., Malmgren R.M., and Dudley J.P. Factors associated with a rapid course of multiple sclerosis. Arch. Neurol. 39 (1982) 337-341
28. Ebers G.C. Prognostic factors for multiple sclerosis: The importance of natural history studies. J. Neurol. 252 Suppl. 3 (2005) 15-20
29. Falaschi P., Martocchia A., Proietti A., D'Urso R., and Antonini G. High incidence of hyperandrogenism-related clinical signs in patients with multiple sclerosis. Neuro. Endocrinol. Lett. 22 (2001) 248-250
30. Filippi M., Horsfield M.A., Morrissey S.P., MacManus D.G., Rudge P., McDonald W.I., and Miller D.H. Quantitative brain MRI lesion load predicts the course of clinically isolated syndromes suggestive of multiple sclerosis. Neurology 44 (1994) 635-641
31. Filippi M., Rovaris M., Inglese M., Barkhof F., De Stefano N., Smith S., and Comi G. Interferon beta-1a for brain tissue loss in patients at presentation with syndromes suggestive of multiple sclerosis: A randomised, double-blind, placebo-controlled trial. Lancet 364 (2004) 1463-1464
32. Fraser C., Klistorner A., Graham S., Garrick R., Billson F., and Grigg J. Multifocal visual evoked potential latency analysis. Predicting progression to multiple sclerosis. Arch. Neurol. 63 (2006) 847-850
33. Frederiksen J.L. Can CSF predict the course of optic neuritis?. Mult. Scler. 4 (1998) 132-135
34. Frohman E.M., Goodin D.S., Calabresi P.A., Corboy J.R., Coyle P.K., Filippi M., Frank J.A., Galetta S.L., Grossman R.I., Hawker K., Kachuck N.J., Levin M.C., et al. The utility of MRI in suspected MS: Report of the Therapeutic and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology 61 (2003) 602-611
35. Fuhr P., Borggrefe-Chappuis A., Schindler C., and Kappos L. Visual and motor evoked potentials in the course of multiple sclerosis. Brain 124 (2001) 2162-2168
36. Ghezzi A. Childhood-juvenile multiple sclerosis: Clinical characteristics and treatment. Expert Rev. Neurother. 5 (2005) 403-411
37. Goodin D.S., Frohman E.M., Garmany Jr. G.P., Halper J., Likosky W.H., Lublin F.D., Silberberg D.H., Stuart W.H., and van den Noort S. Disease modifying therapies in multiple sclerosis: Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and the MS Council for Clinical Practice Guidelines. Neurology 58 (2002) 169-178
38. Held U., Heigenhauser L., Shang C., Kappos L., Polman C., and Lawry Centre for MS Research. Predictors of relapse rate in MS clinical trials. Neurology 65 (2005) 1769-1773
39. Hume A.L., and Waxman S.G. Evoked potentials in suspected multiple sclerosis: Diagnostic value and prediction of clinical course. J. Neurol. Sci. 83 (1988) 191-210
40. Huseby E.S., Sather B., Huseby P.G., and Goverman J. Age-dependent T cell tolerance and autoimmunity to myelin basic protein. Immunity 14 4 (2001) 471-481
41. Iannucci G., Tortorella C., Rovaris M., Sormani M.P., Comi G., and Filippi M. Prognostic value of MR and magnetization transfer imaging findings in patients with clinically isolated syndromes suggestive of multiple sclerosis at presentation. Am. J. Neuroradiol. 21 (2000) 1034-1038
42. Jacobs L.D., Beck R.W., Simon J.H., Kinkel R.P., Brownscheidle C.M., Murray T.J., Simonian N.A., Slasor P.J., and Sandrock A.W. Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis. CHAMPS study group. N. Engl. J. Med. 343 (2000) 898-904
43. Jin Y.P., de Pedro-Cuesta J., Huang Y.H., and Soderstrom M. Predicting multiple sclerosis at optic neuritis onset. Mult. Scler. 9 (2003) 135-141
44. Johnson K.P., Brooks B.R., Cohen J.A., Ford C.C., Goldstein J., Lisak R.P., Myers L.W., Panitch H.S., Rose J.W., Schiffer R.B., Vollmer T., Weiner L.P., et al. Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: Results of a phase III multicenter, double-blind, placebo-controlled trial. Neurology 45 (1995) 1268-1276
45. Kantarci O., Siva A., Eraksoy M., Karabudak R., Sutlas N., Agaoglu J., Turan F., Ozmenoglu M., Togrul E., and Demirkiran M. Survival and predictors of disability in Turkish MS patients. Neurology 51 (1998) 765-772
46. Kappos L., Moeri D., Radue E.W., Schoetzau A., Schweikert K., Barkhof F., Miller D., Guttmann C.R., Weiner H.L., Gasperini C., and Filippi M. Predictive value of gadolinium-enhanced magnetic resonance imaging for relapse rate and changes in disability or impairment in multiple sclerosis: A meta-analysis. Gadolinium MRI Meta-analysis Group. Lancet 353 (1999) 964-969
47. Killestein J., Kalkers N.F., Meilof J.F., Barkhof F., van Lier R.A., and Polman C.H. TNFalpha production by CD4(+) T cells predicts long-term increase in lesion load on MRI in MS. Neurology 57 (2001) 1129-1131
48. Kornek B., and Lassmann H. Neuropathology of multiple sclerosis-new concepts. Brain Res. Bull. 61 (2003) 321-326
49. Korteweg T., Tintore M., Uitdehaag B., Rovira A., Frederiksen J., Miller D., Fernando K., Filippi M., Agosta F., Rocca M., Fazekas F., Enzinger C., et al. MRI criteria for dissemination in space in patients with clinically isolated syndromes: A multicentre follow-up study. Lancet Neurol. 5 (2006) 221-227
50. Kraft G.H., Freal J.E., Coryell J.K., Hanan C.L., and Chitnis N. Multiple sclerosis: Early prognostic guidelines. Arch. Phys. Med. Rehabil. 62 2 (1981) 54-58
51. Kremenchutzky M., Rice G.P., Baskerville J., Wingerchuk D.M., and Ebers G.C. The natural history of multiple sclerosis: A geographically based study 9: Observations on the progressive phase of the disease. Brain 129 (2006) 584-594
52. Kurtzke J.F. Rating neurologic impairment in multiple sclerosis: An expanded disability status scale (EDSS). Neurology 33 (1983) 1444-1452
53. Lauer K., and Firnhaber W. Prognostic criteria in an epidemiological group of patients with multiple sclerosis: An exploratory study. J. Neurol. 239 (1992) 93-97
54. Levic Z.M., Dujmovic I., Pekmezovic T., Jarebinski M., Marinkovic J., Stojsavljevic N., and Drulovic J. Prognostic factors for survival in multiple sclerosis. Mult. Scler. 5 (1999) 171-178
55. Lublin F.D., and Reingold S.C. Defining the clinical course of multiple sclerosis: Results of an international survey. Neurology 46 (1996) 907-911
56. Martinelli V., Rodegher M., Moiola L., and Comi G. Late onset multiple sclerosis: Clinical characteristics, prognostic factors and differential diagnosis. Neurol. Sci. 25 Suppl. 4 (2004) S350-S355
57. Martinez-Yelamos A., Saiz A., Bas J., Hernandez J.J., Graus F., and Arbizu T. Tau protein in cerebrospinal fluid: A possible marker of poor outcome in patients with early relapsing-remitting multiple sclerosis. Neurosci. Lett. 363 (2004) 14-17
58. McDonald W.I., Compston A., Edan G., Goodkin D., Hartung H.-P., Lublin F.D., McFarland H.F., Paty D.W., Polman C.H., Reingold S.C., Sandberg-Wollheim M., Sibley W., et al. Recommended diagnostic criteria for multiple sclerosis: Guidelines from the International Panel on the diagnosis of multiple sclerosis. Ann. Neurol. 50 (2001) 121-127
59. Mikaeloff Y., Adamsbaum C., Husson B., Vallee L., Ponsot G., Confavreux C., Tardieu M., Suissa S., and KIDMUS Study Group on Radiology. MRI prognostic factors for relapse after acute CNS inflammatory demyelination in childhood. Brain 127 (2004) 1942-1947
60. Mikaeloff Y., Suissa S., Vallee L., Lubetzki C., Ponsot G., Confavreux C., Tardieu M., and KIDMUS Study Group. First episode of acute CNS inflammatory demyelination in childhood: Prognostic factors for multiple sclerosis and disability. J. Pediatr. 144 (2004) 246-252
61. Minneboo A., Barkhof F., Polman C.H., Uitdehaag B.M., Knol D.L., and Castelijns J.A. Infratentorial lesions predict long-term disability in patients with initial findings suggestive of multiple sclerosis. Arch. Neurol. 61 (2004) 217-221
62. Morrissey S.P., Miller D.H., Kendall B.E., Kingsley D.P., Kelly M.A., Francis D.A., MacManus D.G., and McDonald W.I. The significance of brain magnetic resonance imaging abnormalities at presentation with clinically isolated syndromes suggestive of multiple sclerosis. A 5-year follow-up study. Brain 116 (1993) 135-146
63. Nilsson P., Larsson E.M., Maly-Sundgren P., Perfekt R., and Sandberg-Wollheim M. Predicting the outcome of optic neuritis: Evaluation of risk factors after 30 years of follow-up. J. Neurol. 252 (2005) 396-402
64. Noseworthy J., Paty D., Wonnacott T., Feasby T., and Ebers G. Multiple sclerosis after age 50. Neurology 33 12 (1983) 1537-1544
65. O'Riordan J.I., Thompson A.J., Kingsley D.P., Macmanus D.G., Kendall B.E., Rudge P., Mcdonald W.I., and Miller D.H. The prognostic value of brain MRI in clinically isolated syndromes of the CNS. A 10-year follow-up. Brain 121 (1998) 495-503
66. O'Riordan J.I., Losseff N.A., Phatouros C., Thompson A.J., Moseley I.F., MacManus D.G., McDonald W.I., and Miller D.H. Asymptomatic spinal cord lesions in clinically isolated optic nerve, brain stem, and spinal cord syndromes suggestive of demyelination. J. Neurol. Neurosurg. Psychiatry 64 (1998) 353-357
67. Optic Neuritis Study Group. The 5-year risk of MS after optic neuritis: Experience of the Optic Neuritis Treatment Trial. Neurology 49 (1997) 1404-1413
68. Paty D.W., Oger J.J.F., Kastrukoff L.F., Hashimoto S.A., Hooge J.P., Eisen A.A., Eisen K.A., Purves S.J., Low M.D., Brandejs V., Robertson W.D., and Li D.K.B. MRI in the diagnosis of MS: A prospective study with comparison of clinical evaluation, evoked potentials, oligoclonal banding, and CT. Neurology 38 (1988) 180-185
69. Phadke J.C. Clinical aspect of multiple sclerosis in North East Scotland with particular reference to its course and prognosis. Brain 113 (1990) 1597-1628
70. Pirko I., Blauwet L.K., Lesnick T.G., and Weinshenker B.G. The natural history of recurrent optic neuritis. Arch. Neurol. 61 (2004) 1401-1405
71. Pittock S.J., McClelland R.L., Mayr W.T., Jorgensen N.W., Weinshenker B.G., Noseworthy J., and Rodriguez M. Clinical implications of benign multiple sclerosis: A 20-year population-based follow-up study. Ann. Neurol. 56 2 (2004) 303-306
72. Polman C., Reingold S., Edan G., Filippi M., Hartung H.P., Kappos L., Lublin F.D., Metz L.M., McFarland H.F., O'connor P.W., Sandberg-Wollheim M., Thompson A.J., et al. Diagnostic Criteria for Multiple Sclerosis: 2005 Revisions to the "McDonald Criteria.". Ann. Neurol. 58 (2005) 840-846
73. Poser S., Raun N.E., and Poser W. Age at onset, initial symptomatology and the course of multiple sclerosis. Acta Neurol. Scand. 66 (1982) 355-362
74. Ramsaransing G., Maurits N., Zwanikken C., and De Keyser J. Early prediction of a benign course of multiple sclerosis on clinical grounds: A systematic review. Mult. Scler. 7 (2001) 345-347
75. Riise T., Gronnig M., Fernandez O., Lauer K., Midgard R., Minderhoud J.M., Nyland H., Palffy G., Poser S., and Aarli J.A. Early prognostic factors for disability in multiple sclerosis: A European multicenter study. Acta Neurol. Scand. 85 (1992) 212-218
76. Rovaris M., and Filippi M. Contrast enhancement and the acute lesion in multiple slcerosis. Neuroimaging Clin. N. Am. 10 (2000) 705-716
77. Rudick R.A., Lee J.C., Simon J., and Fisher E. Significance of T2 lesions in multiple sclerosis: A 13-year longitudinal study. Ann. Neuro. (2006) [Epub June 2006 (ahead to print)]
78. Runmarker B., and Andersen O. Prognostic factors in a multiple sclerosis incidence cohort with twenty five years of follow-up. Brain 116 (1993) 117-134
79. Santos A.C., Narayanan S., de Stefano N., Tartaglia M.C., Francis S.J., Arnaoutelis R., Caramanos Z., Antel J.P., Pike G.B., and Arnold D.L. Magnetization transfer can predict clinical evolution in patients with multiple sclerosis. J. Neurol. 249 (2002) 662-668
80. Sastre-Garriga J., Ingle G.T., Rovaris M., Tellez N., Jasperse B., Altmann D.R., Benedetti B., Stevenson V.L., Cercignani M., Leary S.M., Barkhof F., Brochet B., et al. Long-term clinical outcome of primary progressive MS: Predictive value of clinical and MRI data. Neurology 65 (2005) 633-635
81. Scott T.F., Schramke C.J., Novero J., and Chieffe C. Short-term prognosis in early relapsing-remitting multiple sclerosis. Neurology 55 (2000) 689-693
82. Simone I.L., Carrara D., Tortorella C., Liguori M., Lepore V., Pellegrini F., Bellacosa A., Ceccarelli A., Pavone I., and Livrea P. Course and prognosis in early-onset MS. Comparison with adult-onset forms. Neurology 59 (2002) 1922-1928
83. Smith M.E., Eller N.L., McFarland H.F., Racke M.K., and Raine C.S. Age dependence of clinical and pathological manifestations of autoimmune demyelination. Implications for multiple sclerosis. Am. J. Pathol. 155 4 (1999) 1147-1161
84. Spiegelhalter D.J., Myles J.P., Jones D.R., and Abrams K.R. Methods in health service research. An introduction to Bayesian methods in health technology assessment. BMJ 319 (1999) 508-512
85. Swanton J.K., Fernando K., Dalton C.M., Miskiel K.A., Thompson A.J., Plant G.T., and Miller D.H. Is the frequency of MRI abnormalities in isolated optic neuritis related to the prevalence of multiple sclerosis? A global comparison. J. Neurol. Neurosurg. Psychiatry (2006) [Epub June 2006 (ahead of print)]
86. The IFNB MS Study Group, and the University of British Columbia, MS/MRI Analysis Group. Interferon beta-1b in the treatment of multiple sclerosis: Final outcome of the randomised controlled trial. Neurology 45 (1995) 1277-1285
87. Thompson A.J., Hutchinson M., Brazil J., Feighery C., and Martin E.A. A clinical and laboratory study of benign multiple sclerosis. Q. J. Med New Ser. 58 (1986) 69-80
88. Thorpe J.W., Kidd D., Moseley I.F., Thompson A.J., MacManus D.G., Compston D.A., McDonald W.I., and Miller D.H. Spinal MRI in patients with suspected multiple sclerosis and negative brain MRI. Brain 119 (1996) 709-714
89. Tintore M., Rovira A., Rio J., Nos C., Grivé E., Sastre-Garriga J., Pericot I., Sánchez E., Comabella M., and Montalban X. New diagnostic criteria for multiple sclerosis: Application in first demyelinating episode. Neurology 60 1 (2003) 27-30
90. Tintore M., Rovira A., Rio J., Nos C., Grive E., Tellez N., Pelayo R., Comabella M., and Montalban X. Is optic neuritis more benign than the other first attacks in multiple sclerosis?. Ann. Neurol. 57 (2005) 210-215
91. Tremlett H., Paty D., and Devonshire V. Disability progression in multiple sclerosis is slower than previously reported. Neurology 66 (2006) 172-177
92. Trojano M., Avolio C., Manzari C., Calo A., De Robertis F., Serio G., and Livrea P. Multivariate analysis of predictive factors of multiple sclerosis course with a validated method to assess clinical events. J. Neurol. Neurosurg. Psychiatry 58 (1995) 300-306
93. Trojano M., Liguori M., Bosco Zimatore G., Bugarini R., Avolio C., Paolicelli D., Giuliani F., De Robertis F., Marrosu M.G., and Livrea P. Age-related disability in multiple sclerosis. Ann. Neurol. 51 (2002) 475-480
94. Villar L.M., Masjuan J., Gonzalez-Porque P., Plaza J., Sadaba M.C., Roldan E., Bootello A., and Alvarez-Cermeno J.C. Intrathecal IgM synthesis is a prognostic factor in multiple sclerosis. Ann. Neurol. 53 (2003) 222-226
95. Villar L.M., Sadaba M.C., Roldan E., Masjuan J., Gonzalez-Porque P., Villarrubia N., Espino M., Garcia-Trujillo J.A., Bootello A., and Alvarez-Cermeno J.C. Intrathecal synthesis of oligoclonal IgM against myelin lipids predicts an aggressive disease course in MS. J. Clin. Invest. 115 (2005) 187-194
96. Visscher B.R., Liu K.S., Clark V.A., Detels R., Malmgren R.M., and Dudley J.P. Onset symptoms as predictors of mortality and disability in multiple sclerosis. Acta Neurol. Scand. 70 (1984) 321-328
97. Weinshenker B.G., Bass B., Rice G.P.A., Noseworthy J., Carriere W., Baskerville J., and Ebers G.C. The natural history of multiple sclerosis: A geographically based study. 2. Predictive value of the early clinical course. Brain 112 (1989) 133-146
98. Weinshenker B.G., Rice G.P.A., Noseworthy J.H., Carriere W., Basekerville J., and Ebers G.C. The natural history of multiple sclerosis: A geographically based study. 4. Applications to planning and interpretation of clinical therapeutic trials. Brain 114 (1991) 1057-1067
99. Weinshenker B.G., Issa M., and Baskerville J. Long-term and short-term outcome of multiple sclerosis: A 3-year follow-up study. Arch. Neurol. 53 (1996) 353-358
100. Weinshenker B.G. Bayesian analysis: What does it add to studies of the natural history of MS?. J. Neurol. Sci. 189 (2001) 1-2
101. Wolfson C., and Confavreux C. A improvements to a simple Markov model of the natural history of multiple sclerosis, I. Short term prognosis. Neuroepidemiology 6 (1987) 101-115
102. Zang Y.C., Halder J.B., Hong J., Rivera V.M., and Zhang J.Z. Regulatory effects of estriol on T cell migration and cytokine profile: Inhibition of transcription factor NF-kappa B. J. Neuroimmunol. 124 (2002) 106-114